| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:BMY 45778;[3-(4,5-Diphenyl[2,4'-bioxazol]-5'-yl)phenoxy]aceticacid
CAS:152575-66-1
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:BMY 45778
CAS:152575-66-1
Purity:99% by HPLC Remarks:BMY 45778 is a non-prostanoid prostacyclin mimetic that acts as a partial agonist of IP1 prostacyclin receptors. It inhibits platelet aggregation in vitro (IC50 = 27-35 nM).
|
|
| | BMY 45778 Basic information |
| Product Name: | BMY 45778 | | Synonyms: | [3-(4,5-DIPHENYL[2,4'-BIOXAZOL]-5'-YL)PHENOXY]ACETIC ACID;BMY 45778;Acetic acid, 2-[3-(4,5-diphenyl[2,4'-bioxazol]-5'-yl)phenoxy]-;BMY 45778 >=98% (HPLC) | | CAS: | 152575-66-1 | | MF: | C26H18N2O5 | | MW: | 438.43 | | EINECS: | | | Product Categories: | | | Mol File: | 152575-66-1.mol |  |
| | BMY 45778 Chemical Properties |
| Boiling point | 659.9±65.0 °C(Predicted) | | density | 1.298±0.06 g/cm3(Predicted) | | storage temp. | room temp | | solubility | ≥67.6 mg/mL in DMSO | | pka | 3.10±0.10(Predicted) | | form | powder | | color | white to beige |
| | BMY 45778 Usage And Synthesis |
| Uses | BMY 45778 is an agonist for IP receptor to up-regulate the expression of C?/EBPβ and C?/EBPδ. | | Definition | ChEBI: BMY 45778 is a bisoxazole. It has a role as a partial prostacyclin agonist. | | Biological Activity | Non-prostanoid prostacyclin mimetic that acts as a partial agonist at IP 1 prostacyclin receptors. Potently inhibits platelet aggregation in vitro (IC 50 = 27-35 nM). | | Biochem/physiol Actions | BMY 45778 is a non-prostanoid prostacyclin agonist. | | references | [1]. seiler sm, brassard cl, federici me, et al. [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (bmy 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, camp levels, protein kinase, and iloprost binding. prostaglandins, 1997, 53(1): 21-35.
[2]. wise h, qian ym, jones rl. a study of prostacyclin mimetics distinguishes neuronal from neutrophil ip receptors. eur j pharmacol, 1995, 278(3): 265-269. |
| | BMY 45778 Preparation Products And Raw materials |
|